TY - JOUR
T1 - From Stability to Variability
T2 - Classification of Healthy Individuals, Prediabetes, and Type 2 Diabetes using Glycemic Variability Indices from Continuous Glucose Monitoring Data
AU - Cichosz, Simon Lebech
AU - Kronborg, Thomas
AU - Laugesen, Esben
AU - Hangaard, Stine
AU - Fleischer, Jesper
AU - Hansen, Troels Krarup
AU - Jensen, Morten Hasselstrøm
AU - Poulsen, Per Løgstrup
AU - Vestergaard, Peter
PY - 2024/7
Y1 - 2024/7
N2 - Objective: This study aims to investigate the continuum of glucose control from normoglycemia to dysglycemia (HbA1c ‡ 5.7%/39 mmol/mol) using metrics derived from continuous glucose monitoring (CGM). In addition, we aim to develop a machine learning-based classification model to classify dysglycemia based on observed patterns. Methods: Data from five distinct studies, each featuring at least two days of CGM, were pooled. Participants included individuals classified as healthy, with prediabetes, or with type 2 diabetes mellitus (T2DM). Various CGM indices were extracted and compared across groups. The data set was split 70/30 for training and testing two classification models (XGBoost/Logistic Regression) to differentiate between prediabetes or dysglycemia and the healthy group. Results: The analysis included 836 participants (healthy: n = 282; prediabetes: n = 133; T2DM: n = 432). Across all CGM indices, a progressive shift was observed from the healthy group to those with diabetes (P < 0.001). Statistically significant differences (P < 0.01) were noted in mean glucose, time below range, time above 140 mg/dl, mobility, multiscale complexity index, and glycemic risk index when transitioning from health to prediabetes. The XGBoost models achieved the highest receiver operating characteristic area under the curve values on the test data set ranging from 0.91 [confidence interval (CI): 0.87–0.95] (prediabetes identification) to 0.97 [CI: 0.95–0.98] (dysglycemia identification). Conclusion: Our findings demonstrate a gradual deterioration of glucose homeostasis and increased glycemic variability across the spectrum from normo- to dysglycemia, as evidenced by CGM metrics. The performance of CGM-based indices in classifying healthy individuals and those with prediabetes and diabetes is promising.
AB - Objective: This study aims to investigate the continuum of glucose control from normoglycemia to dysglycemia (HbA1c ‡ 5.7%/39 mmol/mol) using metrics derived from continuous glucose monitoring (CGM). In addition, we aim to develop a machine learning-based classification model to classify dysglycemia based on observed patterns. Methods: Data from five distinct studies, each featuring at least two days of CGM, were pooled. Participants included individuals classified as healthy, with prediabetes, or with type 2 diabetes mellitus (T2DM). Various CGM indices were extracted and compared across groups. The data set was split 70/30 for training and testing two classification models (XGBoost/Logistic Regression) to differentiate between prediabetes or dysglycemia and the healthy group. Results: The analysis included 836 participants (healthy: n = 282; prediabetes: n = 133; T2DM: n = 432). Across all CGM indices, a progressive shift was observed from the healthy group to those with diabetes (P < 0.001). Statistically significant differences (P < 0.01) were noted in mean glucose, time below range, time above 140 mg/dl, mobility, multiscale complexity index, and glycemic risk index when transitioning from health to prediabetes. The XGBoost models achieved the highest receiver operating characteristic area under the curve values on the test data set ranging from 0.91 [confidence interval (CI): 0.87–0.95] (prediabetes identification) to 0.97 [CI: 0.95–0.98] (dysglycemia identification). Conclusion: Our findings demonstrate a gradual deterioration of glucose homeostasis and increased glycemic variability across the spectrum from normo- to dysglycemia, as evidenced by CGM metrics. The performance of CGM-based indices in classifying healthy individuals and those with prediabetes and diabetes is promising.
KW - classification
KW - continuous glucose monitoring
KW - glucose control
KW - glycemic variability
KW - modeling
KW - prediabetes
KW - type 2 diabetes
U2 - 10.1089/dia.2024.0226
DO - 10.1089/dia.2024.0226
M3 - Journal article
SN - 1520-9156
JO - Diabetes Technology & Therapeutics
JF - Diabetes Technology & Therapeutics
ER -